bioMérieux announces the acquisition of Lumed, a software company that has 'created a clinical decision support system designed to support hospitals in optimizing antibiotic prescriptions and monitoring healthcare-associated infections'.

The French in vitro diagnostics specialist is increasing its stake in this Canadian company, with which it has worked closely since 2017, from 16% to 100%, with the acquisition of 84% of the capital representing an investment of almost nine million euros.

According to bioMérieux, Lumed's solutions provide healthcare professionals with a variety of information they need to ensure better patient care, combat antibiotic resistance and improve infection control.

Copyright (c) 2024 CercleFinance.com. All rights reserved.